Patients with certain FTO and MC4R variants, for example, often show enhanced appetite suppression and weight loss when using dual GLP-1/GIP receptor agonists like tirzepatide, potentially allowing metformin reduction or discontinuation more rapidly
:
The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment
doi: 10.1007/s40279-015-0394-8 367 WagenmakersAJ
Coagonistas GLP-1/glucagn El desarrollo de estas formulaciones unimoleculares con efecto sobre los receptores de GLP-1 y glucagn aporta potenciacin del efecto anorexiante de GLP-1, efecto lipoltico e inhibidor de la lipognesis (tabla 2), particularmente a nivel heptico, y accin termognica, facilitando la reduccin ponderal y el tratamiento de MASLD1,5,35
Build the foundation firstsolid nutrition, consistent exercise, adequate sleepthen consider whether supplements provide marginal additional benefits worth pursuing